Gastrointestinal Damage by Cancer Chemotherapy

  • M. Valentini
  • R. Cannizzaro
  • F. Bortoluzzi
  • M. Sozzi
  • M. Fornasarig
  • E. Bertolissi
Conference paper


Injury to the gastrointestinal tract may occur with any number of chemotherapy drugs used for the treatment of malignant disease. Indeed, the dosage of antineoplastic drugs is limited by toxic effects not only on the lungs, kidneys, and bone marrow but also on the liver and gastrointestinal tract. Some gastrointestinal symptoms such nausea, vomiting, anorexia, abdominal pain, and diarrhea may be either the presenting features of the underlying malignancy, usually self-limiting adverse reactions to drugs, or in some cases manifestations of more severe chemotherapy-induced gastrointestinal toxicity. Anticancer drugs as a group are thought preferentially to attack rapidly dividing tissues, including the gastrointestinal mucosa: nevertheless, remarkable little attention has been directed to the gastrointestinal epithelium and to its function in man.


Motion Sickness Antineoplastic Drug Anticipatory Nausea Pneumatosis Cystoides Intestinalis Chemoreceptor Trigger Zone 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Andrews PLR, Rapeport WG, Sanger GJ (1988) Neuropharmacology of emesis induced by anti-cancer therapy. Trends in Pharmacol Sci 9: 334–341CrossRefGoogle Scholar
  2. 2.
    Ansfield FJ, Ramírez G (1978) The clinical results of 5-fluorouracil intrahepatic arterial infusion in 528 patients with metastatic cancer to the liver. Prog Clin Cancer 7: 201–206PubMedGoogle Scholar
  3. 3.
    Bleyer WA (1978) The clinical pharmacology of methotrexate. Cancer 41: 36–51PubMedCrossRefGoogle Scholar
  4. 4.
    Blum RH, Carter SK (1974) Adriamycin: a new anticancer drug with significant clinical activity. Ann Int Med 80: 249–259PubMedGoogle Scholar
  5. 5.
    Borison HL, McCarthy LE (1983) Neuropharmacology of chemotherapy induced emesis. Drugs 2 (Suppl 1): 8–17CrossRefGoogle Scholar
  6. 6.
    Borison HL, Wang WC (1953) Physiology and pharmacology of vomiting. Pharmacol Rev 5: 193–230PubMedGoogle Scholar
  7. 7.
    Bremer K on behalf of the Granisetron Study Group (1992) A single-blind comparative study with alizapride plus dexamethasone in the prophylaxis and control of emesis in patients receiving cytostatic therapy over a 5-day treatment period. Eur J Cancer 28: 1018–1022CrossRefGoogle Scholar
  8. 8.
    Brereton HD, Kent CH, Johnson RE (1979) Chemotherapy and radiation therapy for small cell cancer of the lung: a remedy for past therapeutic failure. In: Muggia F, Rozencweig M (eds) Lung cancer: progress in therapeutic research. Raven, New YorkGoogle Scholar
  9. 9.
    Chevallier B, on behalf of the Granisetron Study Group (1990) Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexametha-sone in patients receiving high-dose cisplatin in a single-blind study. Eur J Cancer 26 (Suppl 1) : S 33–S 37Google Scholar
  10. 10.
    Chu DZJ, Shivshanker K, Stoehlien JR et al. (1983) Thrombocytopenia and gastrointestinal hemorrhage in the cancer patient: prevalance of unmarked lesions. Gastrointest Endosc 29: 269–272PubMedCrossRefGoogle Scholar
  11. 11.
    Craft AW, Kay HZM, Lawson DN et al. (1977) Methotrexate-induced malabsorption in children with acute lymphoblastic leukemia. BMJ 2: 1511–1512PubMedCrossRefGoogle Scholar
  12. 12.
    Cudmore MA, Silva J, Fekety R et al. (1982) Clostridium difficile colitis associates with cancer chemotherapy. Arch Intern Med 142: 333–335PubMedCrossRefGoogle Scholar
  13. 13.
    Cunningham D, Turner A, Hawthorn et al. (1989) Ondasentron with and without dexamethasone to treat chemotherapy-induced emesis (editorial), Lancet i: 1323CrossRefGoogle Scholar
  14. 14.
    D’Acquisto RW, Tyson LB, Gralla RJ et al. (1986) The influence of a chronic high alcohol intake on chemotherapy-induced nausea and vomiting. Proc Am Soc Clin Oncol 5: 257Google Scholar
  15. 15.
    Dana BW, McDermott M, Everts E et al. (1987) A randomized trial of high dose bolus metoclopramide versus low-dose continuous infusion metoclopramide in the prevention of cisplatin induced emesis. Am J Clin Oncol 10: 253–256PubMedCrossRefGoogle Scholar
  16. 16.
    Diehl V on behalf of the Granisetron Study Group (1992) Fractionated chemotherapy-granisetron or conventional antiemetics?. Eur J Cancer 28 A (Suppll): S 21–S 28CrossRefGoogle Scholar
  17. 17.
    Dilly S (1992) Are granisetron and ondasentron equivalent in the clinic? Eur J Cancer 28 A (Suppl 1) : S 32–S 35Google Scholar
  18. 18.
    Donaldson SS, Glick JM, Wilbur SR (1974) Adriamycin activating a recall phenomenon after radiation therapy. Ann Intern Med 81: 407–408PubMedGoogle Scholar
  19. 19.
    Donaldson SS, Lenon RA (1979) Alteration of nutritional status: the impact of chemotherapy and radiation therapy. Cancer 43: 2036–2052PubMedCrossRefGoogle Scholar
  20. 20.
    Dosik GM, Luna M, Valdivieso M et al. (1979) Necrotizing colitis in patients with cancer. Am J Med 67: 646–656PubMedCrossRefGoogle Scholar
  21. 21.
    Durant JR (1984) The problem of nausea and vomiting in modern cancer chemotherapy. CA 34: 2–6PubMedGoogle Scholar
  22. 22.
    Einhorn LE, Nagy C, Werner K et al. (1990) Ondasentron: a new antiemetic for patients receiving cisplatin chemotherapy. J Clin Oncol 8: 731–735PubMedGoogle Scholar
  23. 23.
    Faloon WW (1970) Drug production of intestinal malabsorption. NY State J Med 70: 2189–2192Google Scholar
  24. 24.
    Fetting JH, Grochow LB, Folstein MF et al. (1982) The course of nausea and vomiting after high dose cyclophosphamide. Cancer Treat Rev 66: 1487–1493Google Scholar
  25. 25.
    Freeman HJ, Rabeneck L, Owen D (1981) Survival after necrotizing enterocolitis of leukemia treated with oral vancomycin. Gastroenterology 81: 791–794PubMedGoogle Scholar
  26. 26.
    Freeman AJ, Cullen MH (1991) Advances in the management of cytotoxic drug-induced nausea and vomiting. J Clin Pharm Ther 16: 411–421PubMedCrossRefGoogle Scholar
  27. 27.
    Gralla RJ, Tyson LB, Kriss MG et al. (1987) The management of chemotherapy induced nausea and vomiting. Med Clin North Am 71: 289–301PubMedGoogle Scholar
  28. 28.
    Gralla RJ (1989) An outline of anti-emetic treatment. Eur J Cancer 25 (Suppl 1) : S 7–S 11Google Scholar
  29. 29.
    Greco FA, Brereton HD, Kent H et al. (1976) Adriamycin and enhanced radiation reaction in normal esophagus and skin. Ann Intern Med 85: 294–298PubMedGoogle Scholar
  30. 30.
    Gwavava NJT, Pinkerton CR, Glasgow JFT et al. (1981) Small bowel enterocyte abnormalities caused by methotrexate treatment in acute lymphoblastic leukemia of childhood. J Clin Pathol 34: 790–795PubMedCrossRefGoogle Scholar
  31. 31.
    Harris JG (1978) Nausea, vomiting and cancer treatment. CA 28: 194–201PubMedGoogle Scholar
  32. 32.
    Hoagland AC, Morrow GR, Bennet JM et al. (1983) Oncologists views of cancer patient noncompliance. Am J Clin Oncol 6: 239–244PubMedCrossRefGoogle Scholar
  33. 33.
    Hohn DC, Stagg RJ, Price DC et al. (1985) Avoidance of gastroduodenal toxicity in patients receiving hepatic arterial 5-fluoro-2’-deoxyuridine. J Clin Oncol 3 (N. 9): 1257–1260PubMedGoogle Scholar
  34. 34.
    Holland JF, Scharlau C, Gailani S et al. (1973) Vincristine treatment of advanced cancer: a cooperative study of 392 cases. Can Res 33: 1258–1264Google Scholar
  35. 35.
    Kearsley JH, Williams AM, Fiumara AM (1989) Antiemetic superiority of lora-zepam over oxazepam and methylprednisolone as premedicants for patients receiving cisplatin-containing chemotherapy. Cancer 64: 1595–1599PubMedCrossRefGoogle Scholar
  36. 36.
    Krakoff IH (1987) Cancer chemotherapeutic agents. CA 37: 93–105PubMedGoogle Scholar
  37. 37.
    Kris MG, Tyson LB, Gralla RJ (1983) Extrapyramidal reactions with high-dose metoclopramide. N Engl J Med 309: 433PubMedGoogle Scholar
  38. 38.
    Kris MG, Gralla RJ, Clark RA et al. (1985) Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol 3: 1379–1384PubMedGoogle Scholar
  39. 39.
    Laszlo J (ed) (1983) Antiemetics and cancer chemotherapy. Williams and Wil-kins, Baltimore, pp. 1–5Google Scholar
  40. 40.
    Laszlo J, Lucas VS (1981) Emesis as a critical problem in chemotherapy. N Engl J Med 305: 148–149CrossRefGoogle Scholar
  41. 41.
    Lewis JH et al. (1986) Gastrointestinal Injury Due to Medicinal Agents. Am J Gastroenterol 9: 819–834Google Scholar
  42. 42.
    Lindley CM, Bernard S, Fields SM (1989) Incidence and duration of chemotherapy-induced nausea and vomiting in the outpatient oncology population. J Clin Oncol 7: 1142–1149PubMedGoogle Scholar
  43. 43.
    Marty M (1989) Ondasentron in the prophylaxis of acute cisplatin induced nausea and vomiting. Eur J Cancer 25 (Suppl 1): S 41-S 45Google Scholar
  44. 44.
    Marty M on behalf of the Granisetron Study Group (1990) A comparative study of the use of granisetron, a selective 5HT-3 antagonist, versus a standard antiemetic regimen of chlorpromazine plus dexamethasone in the treatment of cytostatic-induced emesis. Eur J Cancer 26: S 28–S 33Google Scholar
  45. 45.
    Marty M, Pouillart P, Scholl S et al. (1990) Comparison of the 5-hydroxytryptamine 3 (serotonin) antagonist ondasentron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 322: 816–821PubMedCrossRefGoogle Scholar
  46. 46.
    Marty M, On behalf of the Granisetron Study Group (1992) A comparison of granisetron as a single agent with conventional combination antiemetic therapies in the treatment of cytostatic-induced emesis. Eur J Cancer 28 A (Suppl 1): S 12–S 16Google Scholar
  47. 47.
    Mavligit GM, Faintuch J, Levin B et al. (1987) Gastroduodenal mucosal injury during hepatic arterial infusion of chemotherapeutic agents. Gastroenterology 92: 566–569PubMedGoogle Scholar
  48. 48.
    McDonald GB, Tirumali N (1984) Intestinal and liver toxicity of antineoplastic drugs. West J Med 140: 250–259PubMedGoogle Scholar
  49. 49.
    Mitchell EP, Schein PS (1982) Gastrointestinal toxicity of chemotherapeutic agents. Semin Oncol 9: 52–644PubMedGoogle Scholar
  50. 50.
    Morrow GR (1982) Prevalence and correlates of anticipatory nausea and vomiting in chemotherapy patients. J Natl Cancer Inst 68: 585–588PubMedGoogle Scholar
  51. 51.
    Morrow GR (1987) Management of nausea in the cancer patient. In: Rosenthal S, Carignan JR, Smith BD (eds) Medical care of the cancer patient. Saunders, Philadelphia, pp. 381–388Google Scholar
  52. 52.
    Morrow GR (1989) Chemotherapy-Related Nausea and Vomiting: Etiology and Management. CA 39: 102–103Google Scholar
  53. 53.
    Navari RM (1989) Comparison of intermittent versus continuous infusion metoclopramide in control of acute nausea induced by cisplatin chemotherapy. J Clin Oncol 7: 943–946PubMedGoogle Scholar
  54. 54.
    Olver IN, Simon RM, Aisner J (1986) Antiemetic studies: a methodological discussion. Cancer Treat Rep 70: 555–563PubMedGoogle Scholar
  55. 55.
    Pendergrass K, Hainsworth J, Harvey W et al. (1990) Ondasentron (OND): more effective than metoclopramide (MCP) in the prevention of cispla-tin (DDP)-induced nausea (N) and vomiting (V). Proc Am Soc Clin Oncol 9: 319Google Scholar
  56. 56.
    Penta J, Poster D, Bruno S (1983) The pharmacologic treatment of nausea and vomiting caused by cancer chemotherapy: a review. In: Laszlo J (ed) Antiemetics and cancer chemotherapy. Williams and Wilkins, Baltimore, pp. 53–92Google Scholar
  57. 57.
    Philips RKS, Glazer G, Borriello SP (1981) Non-Clostridium difficile pseudomembranous colitis responding to both vancomycin and metronidazole. BMJ 283: 823CrossRefGoogle Scholar
  58. 58.
    Priostman TJ (1989) Clinical studies with ondasentron in the control of radiation induced emesis. Eur J Cancer 25 (Suppl 1): S 29–S 33Google Scholar
  59. 59.
    Riddell RH (1982) The gastrointestinal tract. In: Riddell RD (ed) Pathology of drug-induced and toxic disease. Churchill Livingstone, New York, pp. 515–605Google Scholar
  60. 60.
    Roila F, Tonato M, Basurto C et al. (1987) Anti-emetic activity of high-doses of metoclopramide alone in cisplatin treated cancer patients: a randomized double-blind trial of the Italian oncology group for clinical research. J Clin Oncol 5: 141–149PubMedGoogle Scholar
  61. 61.
    Roila F, Boschetti E, Tonato M et al. (1991) Predictive factors of delayed emesis in cisplatin-treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone. Am J Clin Oncol 14: 238–242PubMedCrossRefGoogle Scholar
  62. 62.
    Rosenthal S, Kaufman S (1975) Vincristine neurotoxocity. Ann Intern Med 80: 733–737Google Scholar
  63. 63.
    Sandler SG, Tobin W, Henderson ES (1969) Vincristine induced neuropathy: a clinical study of fifty leukemia patients. Neurology (Minneapolis) 19: 367–374Google Scholar
  64. 64.
    Schmoll HJ (1989) The role of ondasentron in the treatment of emesis induced by non-cisplatin-containing chemotherapy regimens. Eur J Cancer 25 (Suppl 1): S 35–S 39Google Scholar
  65. 65.
    Schoenfield LF, Lachin JM (1981) The Steering Committee. Chenodiol (cheno-deoxycholic acid) for dissolution of gallstones: The National Cooperative Gallstone Study. A controlled trial of efficacy and safety. Ann Intern Med 95: 257–282PubMedGoogle Scholar
  66. 66.
    Shaw MT, Spector MH, Ladman AJ (1979) Effects of cancer, radiotherapy and cytotoxic drugs on intestinal structure and function. Cancer Treat Rev 6: 141–151PubMedCrossRefGoogle Scholar
  67. 67.
    Sherlock P (ed) (1979) Effect of cancer treatment on nutrition and gastrointestinal function. Clin Bull 9: 136–145Google Scholar
  68. 68.
    Shike M, Gillin JS, Kemeny N et al. (1986) Severe gastroduodenal ulcerations complicating hepatic artery infusion chemotherapy for metastatic colon cancer. Am J Gastroenterol 81: 176–179PubMedGoogle Scholar
  69. 69.
    Slavin RE, Dias MA, Sarai R (1979) Cytosine arabinoside induced gastrointestinal toxic alterations in sequential chemotherapeutic protocols. A clinic pathologic study of 33 patients. Cancer 42: 1747–1759CrossRefGoogle Scholar
  70. 70.
    Sledge GW (1990) Chemotherapy-induced nausea and vomiting. Curr Opin Oncol 2: 909–914PubMedCrossRefGoogle Scholar
  71. 71.
    Sledge GW, Einhorn LH, Nagy C et al. (1990) Randomized trial of ondasentron (OND) and metoclopramide (MCP) as antiemetic therapy for cisplatin-based chemotherapy. Proc Am Soc Clin Oncol 9: 323Google Scholar
  72. 72.
    Smith DB, Newlands ES, Spruyt OW et al. (1990) Ondasentron (GR38032F) plus dexamethasone: effective anti-emetic prophylaxis for patients receiving cytotoxic chemotherapy. Br J Cancer 61: 323–324PubMedCrossRefGoogle Scholar
  73. 73.
    Smith IE on behalf of the Granisetron Study Group (1990) A comparison of two dose levels of granisetron in patients receiving moderately emetogenic cytostatic chemotherapy. Eur J Cancer 26 (Suppl 1): S 20–S 24Google Scholar
  74. 74.
    Smith FP, Kisner DL, Widerlite L et al. (1979) Chemotherapeutic alteration of small intestinal morphology and function: a progress report. J Clin Gastroenterol 1: 203–207PubMedCrossRefGoogle Scholar
  75. 75.
    Soukop M on behalf of the Granisetron Study Group (1990) Comparison of two dose levels of granisetron in patients receiving high-dose cisplatin. Eur J Cancer 26 (Suppl 1) : S 16–S 20Google Scholar
  76. 76.
    Sullivan JR, Leyden MJ, Bell R (1983) Decreased cisplatin-induced nausea and vomiting with chronic alcohol ingestion. N Engl J Med 309: 796PubMedGoogle Scholar
  77. 77.
    Trier JS (1962) Morphologic alterations induced by methotrexate in the mucosa of human proximal intestine. Gastroenterology 43: 407–424PubMedGoogle Scholar
  78. 78.
    Tyers MB, Bunce KT, Humphrey PPA (1989) Pharmacological and anti-emetic properties of ondasentron. Eur J Cancer 25 (Suppl 1): S 15–S 19Google Scholar
  79. 79.
    Wagner ML, Rosenberg HS, Fernbach DJ et al. (1970) Typhlitis: a complication of leukemia in childhood. AJR 109: 341–350Google Scholar
  80. 80.
    Warrington PS, Allan SG, Cornbleet MA et al. (1988) Optimizing anti-emesis in cancer chemotherapy: efficacy of continuous versus intermittent infusion of high dose metoclopramide in emesis induced by cisplatin. BMJ 293: 1334–1337CrossRefGoogle Scholar
  81. 81.
    Weiss H, Walker M, Wiernik P (1974) Neurotoxicity of commonly used antineoplastic agents. N Engl J Med 291: 75–81, 127–133PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1993

Authors and Affiliations

  • M. Valentini
    • 1
  • R. Cannizzaro
    • 1
  • F. Bortoluzzi
    • 1
  • M. Sozzi
    • 1
  • M. Fornasarig
    • 1
  • E. Bertolissi
    • 1
  1. 1.Division of Gastroenterology and Digestive EndoscopyRegional Cancer CenterAvianoItaly

Personalised recommendations